A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
a study on Lung Cancer Non-Small Cell Lung Cancer Stomach Cancer Gastroesophageal Junction Cancer Hodgkin's Lymphoma Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma T Cell Lymphoma Skin Cancer/Melanoma Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Bladder Cancer Ovarian Cancer Breast Cancer Triple-Negative Breast Cancer Cervical Cancer Carcinoma Head and Neck Cancer
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer, NSCLC, cHL, HNSCC, TNBC, DLBCL, PTCL-NOS, Seattle Genetics, Lymphoma, Carcinoma, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck, Stomach Neoplasms, Brentuximab Vedotin, SEA-TGT, sasanlimab
Lead Scientist at University of California Health
- Michael Cheng (ucsf)
Dr. Michael L. Cheng is an academic medical oncologist and Assistant Professor at the University of California, San Francisco (UCSF), where he leads clinical and translational research focused on advancing discoveries in cancer genomics and developing improved therapies for thoracic malignancies, especially Non-Small Cell Lung Cancer (NSCLC). Dr. Cheng received his M.D.
- accepting new patients
- Start Date
- Completion Date
- Seagen Inc.
- Phase 1 research study
- Study Type
- Expecting 417 study participants
- Last Updated